Pean P, Madec Y, Nerrienet E, Borand L, Laureillard D, et al.
2023-10-13 • Pathogens
2023-10-13 • Pathogens
IRIS is a common complication in HIV-infected patients treated for tuberculosis (TB) and cART. Our aim was to evaluate NK cell reconstitution in HIV-infected patients with TB-IRIS compar...
Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A, et al.
2023-06-01 • Lancet Global Health
2023-06-01 • Lancet Global Health
BACKGROUND Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily availab...
Bonnet MMB, Gabillard D, Domoua SK, Muzoora C, Messou E, et al.
2023-03-08 • Clinical Infectious Diseases
2023-03-08 • Clinical Infectious Diseases
BACKGROUND In people with HIV (PWH), the WHO-recommended tuberculosis four-symptom screen (W4SS) targeting those who need molecular rapid test may be suboptimal. We assessed the perf...
Laureillard D, Marcy O, Madec Y, Chea S, Chan S, et al.
2013-10-23 • AIDS
2013-10-23 • AIDS
To analyze cases of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) in the CAMbodian Early versus Late Introduction of Antiretrovirals (CAMELIA)...
Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al.
2011-10-20 • New England Journal of Medicine
2011-10-20 • New England Journal of Medicine
Tuberculosis remains an important cause of death among patients infected with the human immunodeficiency virus (HIV). Robust data are lacking with regard to the timing for the initiation...
Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, et al.
2014-08-01 • Clinical Infectious Diseases
2014-08-01 • Clinical Infectious Diseases
Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency vir...
Blanc FX, Badje AD, Bonnet MMB, Gabillard D, Messou E, et al.
2020-06-18 • New England Journal of Medicine
2020-06-18 • New England Journal of Medicine
BACKGROUND In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already seve...
Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, et al.
2008-09-11 • Antiviral therapy
2008-09-11 • Antiviral therapy
BACKGROUND The long-term maintenance of antiretroviral therapy (ART) remains an important issue, especially in limited-resource settings where additional barriers exist. A cross-sect...
Borand L, Madec Y, Laureillard D, Chou M, Marcy O, et al.
2014-03-07 • PLOS One
2014-03-07 • PLOS One
OBJECTIVE To assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.
Pean P, Nouhin J, Ratana M, Madec Y, Borand L, et al.
2019-08-27 • Frontiers in Immunology
2019-08-27 • Frontiers in Immunology
Background: Human Immunodeficiency Virus 1 (HIV-1) and Mycobacterium Tuberculosis (Mtb) co-infected patients are commonly at risk of immune reconstitution inflammatory syndrome (IRIS) wh...
Madec Y, Laureillard D, Pinoges LLP, Fernandez MAL, Prak N, et al.
2007-01-30 • AIDS
2007-01-30 • AIDS
BACKGROUND: HAART efficacy was evaluated in a real-life setting in Phnom Penh (Médecins Sans Frontières programme) among severely immuno-compromised patients. METHODS: Factors associated...
Ferradini LLF, Laureillard D, Prak N, Ngeth C, Fernandez MAL, et al.
2007-11-12 • AIDS
2007-11-12 • AIDS
OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunologica...
